Current advancement on diagnosis of ovarian cancer using biosensing of CA 125 biomarker: Analytical approaches

Publication date: Available online 31 August 2018Source: TrAC Trends in Analytical ChemistryAuthor(s): Nasrin Razmi, Mohammad HasanzadehAbstractOvarian cancer, as the most leading gynecological malignancy, has a highest morbidity rate worldwide and is associated with the concentrations of CA 125 antigen present, the suggested biomarker by National Cancer Institute (NCI), in blood. Clinically, the range of Mucin 16 (MUC16 or CA 125), a blood-circulating antigen, above threshold (normally less than 35 U/mL) has been linked with ovarian carcinoma and its progression. Studies revealed that 90% of women may test positive for CA 125 when they were diagnosed with the cancer. Therefore, detection of CA125 levels holds clinical significance for diagnosis of ovarian cancer stages and monitoring the therapy responses in patients. Although available clinical conventional assays for CA 125 detection including, radiometric immunoassay, enzyme linked immuno-sorbent assay and fluorescence show high sensitivity and specificity, but they are expensive, time consuming, and require complicated operations with several separation steps, sophisticated instrumentation and experienced personnel. Thus, there is an utmost need of costless, portable, less time consuming and precise method for early CA 125 determination and screening to achieve an effective ovarian cancer diagnosis. Recently, biosensors has received utmost significance in healthcare field. Advances in biological techniques, instrumentati...
Source: TrAC Trends in Analytical Chemistry - Category: Chemistry Source Type: research